{"id":83339,"date":"2025-12-09T10:30:22","date_gmt":"2025-12-09T10:30:22","guid":{"rendered":"https:\/\/www.cofb.org\/?p=83339"},"modified":"2025-12-17T11:48:00","modified_gmt":"2025-12-17T11:48:00","slug":"farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/","title":{"rendered":"Farmac\u00e9uticos hospitalarios se actualizan en el COFB en una nueva edici\u00f3n de la formaci\u00f3n en oncolog\u00eda hematol\u00f3gica"},"content":{"rendered":"

A lo largo del mes de noviembre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB)<\/strong> organiz\u00f3 una nueva edici\u00f3n del curso \u201cActualizaci\u00f3n en oncolog\u00eda hematol\u00f3gica\u201d, con la colaboraci\u00f3n de la Sociedad Catalana de Farmacia Cl\u00ednica (SCFC)<\/a><\/strong> y con el patrocinio de AstraZeneca<\/strong><\/a>, Bristol Myers Squibb <\/a><\/strong>y Janssen<\/strong><\/a>. El vocal de Hospitales del COFB, David Conde<\/strong>, coordin\u00f3 y moder\u00f3 el curso dirigido a farmac\u00e9uticos y farmac\u00e9uticas de hospitales.<\/p>\n\n\n\n

Los objetivos<\/strong> de la formaci\u00f3n fueron actualizar la gesti\u00f3n y el tratamiento de los diferentes c\u00e1nceres hematol\u00f3gicos<\/strong> y revisar los aspectos relacionados con la atenci\u00f3n farmac\u00e9utica<\/strong> en la dispensaci\u00f3n de tratamientos<\/strong> para combatir este tipo de c\u00e1nceres.<\/p>\n\n\n\n

\"El<\/a>
El vocal de Hospitales del COFB, David Conde, durante la presentaci\u00f3n del curso "Actualizaci\u00f3n en oncolog\u00eda hematol\u00f3gica".<\/figcaption><\/figure>\n\n\n\n

David Conde afirm\u00f3 que, ante la buena acogida por los asistentes, "los cursos de actualizaci\u00f3n en enfermedades hematol\u00f3gicas comienzan a ser una tradici\u00f3n anual. Este a\u00f1o se ha puesto el foco en el mieloma m\u00faltiple<\/strong> con dos sesiones: el linfoma folicular<\/strong> y el linfoma de c\u00e9lulas del manto<\/strong>\u201d.<\/p>\n\n\n\n

El vocal de Hospitales del COFB remarc\u00f3 que el curso \u201cha permitido ofrecer una visi\u00f3n esencial de la r\u00e1pida evoluci\u00f3n de la oncolog\u00eda hematol\u00f3gica<\/strong>, con nuevas actualizaciones en el futuro. El curso confirma que el objetivo de la curaci\u00f3n o control de la enfermedad<\/strong>, antes inalcanzable en varias hemopat\u00edas, es ahora un horizonte terap\u00e9utico real\u201d.<\/p>\n\n\n\n

Combinaciones de f\u00e1rmacos frente al mieloma m\u00faltiple de nuevo diagn\u00f3stico<\/h2>\n\n\n\n

En la primera sesi\u00f3n del curso, que tuvo lugar el 6 de noviembre, el jefe del Servicio de Hematolog\u00eda del Hospital Cl\u00ednic, Carlos Fern\u00e1ndez<\/strong>, se focaliz\u00f3 en el tratamiento del mieloma m\u00faltiple en pacientes triples<\/strong>: \u201cel pron\u00f3stico empeora con cada l\u00ednea de terapia sucesiva, con una supervivencia libre de progresi\u00f3n<\/strong> (mPFS) para los triple-refractarios de entre 3,4 y 4,6 meses. Ante este escenario, se ha expandido el arsenal terap\u00e9utico con inmunoterapias innovadoras\u201d.<\/p>\n\n\n\n

\"L'hemat\u00f2leg<\/a>
El hemat\u00f3logo Carlos Fern\u00e1ndez durante su exposici\u00f3n sobre el mieloma m\u00faltiple en pacientes triples.<\/figcaption><\/figure>\n\n\n\n

A continuaci\u00f3n, Larrea analiz\u00f3 el potencial de las terapias de c\u00e9lulas T con receptor de ant\u00edgeno quim\u00e9rico<\/strong> (CAR-T) dirigidas a BCMA (ide-cielo, cilta-cielo) y los anticuerpos biespec\u00edficos<\/strong> (BsAb) dirigidos a BCMA (teclistamab, elranatamab) o GPRC5D (talquetamab). Se\u00f1al\u00f3 que estas nuevas terapias han demostrado altas tasas de respuesta<\/strong>, pero conllevan la necesidad de gestionar toxicidades espec\u00edficas como el s\u00edndrome de liberaci\u00f3n de citocinas (CRS), la neurotoxicidad (ICANS) y el riesgo de infecciones por citopenias persistentes.<\/p>\n\n\n\n

Tratamiento del mieloma m\u00faltiple recividante\/refractario<\/h2>\n\n\n\n

El 13 de noviembre, en la segunda sesi\u00f3n del curso, Albert Oriol<\/strong>, hemat\u00f3logo de el Instituto Catal\u00e1n de Oncolog\u00eda Josep Carreras Research Institute<\/strong>, centr\u00f3 su ponencia con el mieloma m\u00faltiple de nuevo diagn\u00f3stico<\/strong>: \u201cel tratamiento inicial ha pivotado hacia las combinaciones de cuatro f\u00e1rmacos<\/strong> (cuadruplets), que incluyen un anticuerpo monoclonal anti-CD38, un inhibidor del proteasoma (IP), un agente inmunomodulador (IMID) y un corticoide. El objetivo fundamental de esta intensificaci\u00f3n es conseguir una respuesta profunda y r\u00e1pida<\/strong>, especialmente la negatividad de la enfermedad residual m\u00ednima (MRD)\u201d.<\/p>\n\n\n\n

\"\"<\/a>
El doctor Albert Oriol durante su presentaci\u00f3n ligada a mieloma m\u00faltiplo de nuevo diagn\u00f3stico.<\/figcaption><\/figure>\n\n\n\n

En cuanto a la elecci\u00f3n de la combinaci\u00f3n ideal de f\u00e1rmacos<\/strong>, el hemat\u00f3logo comparti\u00f3 que todo depende de la idoneidad para el trasplante aut\u00f3logo de c\u00e9lulas madre <\/strong>(ASCT), los cu\u00e1druplets han mostrado beneficio en la profundidad de la respuesta en todos los perfiles de pacientes. Un aspecto cr\u00edtico mencionado es que la combinaci\u00f3n de IMIDs<\/strong> y anticuerpos anti-CD38<\/strong> aumenta significativamente el riesgo de infecciones, principalmente neumon\u00eda, sobre todo durante los primeros 3-6 meses.<\/p>\n\n\n\n

Actualizaci\u00f3n sobre el linfoma de c\u00e9lulas del manto<\/h2>\n\n\n\n

La Dra. Ana Mar\u00edn<\/strong>, hemat\u00f3loga del Vall d'Hebron Instituto de Oncolog\u00eda, comparti\u00f3 el 20 de noviembre una actualizaci\u00f3n sobre el linfoma de c\u00e9lulas del manto<\/strong> (LCM). Indic\u00f3 que, hist\u00f3ricamente, el LCM se ha considerado incurable, pero se vive un cambio de paradigma con la introducci\u00f3n de los inhibidores de la tirosina cinasa de Bruton (iBTK) en el tratamiento de primera l\u00ednea (1L). En pacientes j\u00f3venes aptos, el ensayo TRIANGLE demostr\u00f3 que a\u00f1adir ibrutinib al est\u00e1ndar de tratamiento (SOC) mejora la supervivencia, lo que pone en cuesti\u00f3n la necesidad del trasplante aut\u00f3logo de c\u00e9lulas madre (ASCT) en la actualidad.<\/p>\n\n\n\n

\"L'hemat\u00f2loga<\/a>
La hemat\u00f3loga Ana Mar\u00edn en un momento del curso "Actualizaci\u00f3n en oncolog\u00eda hematol\u00f3gica"<\/figcaption><\/figure>\n\n\n\n

En pacientes mayores o no aptos para trasplante<\/strong>, Mar\u00edn hizo referencia al ensayo ECHO (acalabrutinib + R-Bendamustina), donde se mostr\u00f3 una mejora en la PFS. Explic\u00f3 que "en el escenario de reca\u00edda\/refractariedad (R\/R), los iBTK covalentes son el nuevo est\u00e1ndar de tratamiento. Para los pacientes que recaen despu\u00e9s del iBTK, las opciones de rescate incluyen la terapia CAR-T (brexucel) y el pirtobrutinib (un iBTK no covalente). precoces\u201d.<\/p>\n\n\n\n

\u00daltimas novedades ligadas al linfoma folicular<\/h2>\n\n\n\n

Por \u00faltimo, en la \u00faltima sesi\u00f3n que se celebr\u00f3 el 27 de noviembre, el doctor Juan Manuel Sancho<\/strong> (ICO-Hospital Germans Trias i Pujol) hizo la presentaci\u00f3n sobre el linfoma folicular (LF): \u201cla toma de decisiones en el LF se basa en el estadio y la carga tumoral, utilizando criterios como los de GELF. Para el LF avanzado con alta carga tumoral, el est\u00e1ndar sigue siendo la inmunoquimioterapia (como rituximab.<\/p>\n\n\n\n

\"El<\/a>
El doctor Juan Manuel Sancho durante su intervenci\u00f3n ligada al linfoma folicular.<\/figcaption><\/figure>\n\n\n\n

El uso de rituximab<\/strong> como mantenimiento<\/strong>, "aunque mejora significativamente la supervivencia libre de progresi\u00f3n (PFS), no ha mostrado un impacto claro en la supervivencia global (OS) a largo plazo", afirm\u00f3 Sancho. En el contexto de la reca\u00edda\/refractariedad (R\/R)<\/strong>, especialmente para pacientes con progresi\u00f3n precoz (POD24), el doctor recalc\u00f3 que "la opci\u00f3n de lenalidomida m\u00e1s rituximab (R2) ha mejorado la PFS. Para las reca\u00eddas posteriores, las opciones de tratamiento incluyen los anticuerpos biespec\u00edficos (mosunetuzumab, epcoritamab) y las et axicabtagene ciloleucel, lisocabtagene maraleucel), que ofrecen altas tasas de respuesta\u201d.<\/p>\n\n\n\n

Con la colaboraci\u00f3n de:<\/strong><\/p>\n\n\n\n

\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure><\/div>\n<\/div>\n<\/div>\n\n\n\n

Con el patrocinio de:<\/strong><\/p>\n\n\n\n

\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

A lo largo de noviembre, el Colegio de Farmac\u00e9uticos de Barcelona (COFB) organiz\u00f3 una nueva edici\u00f3n del curso \u201cActualizaci\u00f3n en oncolog\u00eda hematol\u00f3gica\u201d, con la colaboraci\u00f3n de la Sociedad Catalana de Farmacia Cl\u00ednica (SCFC) y con el patrocinio de AstraZeneca, Bristol Myers Squibb y Janssen. El vocal de Hospitales del COFB, [\u2026]<\/p>","protected":false},"author":10,"featured_media":83398,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[3127,18,19,50,122,70,5425,1044,1046,63],"class_list":["post-83339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-actualitzacio","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-diagnostic","tag-farmaceutics-hospitalaris","tag-formacio","tag-linfoma","tag-mieloma","tag-oncologia-hematologica","tag-tractament"],"yoast_head":"\nFarmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/es\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Farmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/es\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-09T10:30:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-17T11:48:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1383\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Xavier Magraner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Xavier Magraner\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\"},\"author\":{\"name\":\"Xavier Magraner\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4\"},\"headline\":\"Farmac\u00e8utics hospitalaris s’actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica\",\"datePublished\":\"2025-12-09T10:30:22+00:00\",\"dateModified\":\"2025-12-17T11:48:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\"},\"wordCount\":1116,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg\",\"keywords\":[\"actualitzaci\u00f3\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"diagn\u00f2stic\",\"farmac\u00e8utics hospitalaris\",\"Formaci\u00f3\",\"linfoma\",\"mieloma\",\"oncologia hematol\u00f2gica\",\"tractament\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\",\"url\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\",\"name\":\"Farmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg\",\"datePublished\":\"2025-12-09T10:30:22+00:00\",\"dateModified\":\"2025-12-17T11:48:00+00:00\",\"description\":\"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg\",\"width\":2560,\"height\":1383,\"caption\":\"Blood cells\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Farmac\u00e8utics hospitalaris s’actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4\",\"name\":\"Xavier Magraner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g\",\"caption\":\"Xavier Magraner\"},\"url\":\"https:\/\/www.cofb.org\/es\/author\/xmagraner\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Farmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/es\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/","og_locale":"es_ES","og_type":"article","og_title":"Farmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d","og_url":"https:\/\/www.cofb.org\/es\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2025-12-09T10:30:22+00:00","article_modified_time":"2025-12-17T11:48:00+00:00","og_image":[{"width":2560,"height":1383,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg","type":"image\/jpeg"}],"author":"Xavier Magraner","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"Xavier Magraner"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/"},"author":{"name":"Xavier Magraner","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4"},"headline":"Farmac\u00e8utics hospitalaris s’actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica","datePublished":"2025-12-09T10:30:22+00:00","dateModified":"2025-12-17T11:48:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/"},"wordCount":1116,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg","keywords":["actualitzaci\u00f3","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","diagn\u00f2stic","farmac\u00e8utics hospitalaris","Formaci\u00f3","linfoma","mieloma","oncologia hematol\u00f2gica","tractament"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/","url":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/","name":"Farmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg","datePublished":"2025-12-09T10:30:22+00:00","dateModified":"2025-12-17T11:48:00+00:00","description":"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg","width":2560,"height":1383,"caption":"Blood cells"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Farmac\u00e8utics hospitalaris s’actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4","name":"Xavier Magraner","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g","caption":"Xavier Magraner"},"url":"https:\/\/www.cofb.org\/es\/author\/xmagraner\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg",2560,1383,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-300x162.jpg",300,162,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-768x415.jpg",768,415,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-1024x553.jpg",1024,553,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-1536x830.jpg",1536,830,true],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-2048x1106.jpg",2048,1106,true],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-18x10.jpg",18,10,true]},"uagb_author_info":{"display_name":"Xavier Magraner","author_link":"https:\/\/www.cofb.org\/es\/author\/xmagraner\/"},"uagb_comment_info":0,"uagb_excerpt":"Al llarg del mes de novembre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va organitzar una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) i amb el patrocini d\u2019AstraZeneca, Bristol Myers Squibb i Janssen. El vocal d\u2019Hospitals del COFB, […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/83339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=83339"}],"version-history":[{"count":42,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/83339\/revisions"}],"predecessor-version":[{"id":83426,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/83339\/revisions\/83426"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media\/83398"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=83339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=83339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=83339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}